The Sandoz therapy now has received an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower quantity having been granted approval in June 2015.
The US Food and Drug Administration has granted approval to glatiramer acetate injection (Glatopa, Sandoz) 40 mg/mL for the treatment of relapsing forms of multiple sclerosis (MS).
The injection therapy now has received an indication for use in either 40 mg/mL or 20 mg/mL doses, with the lower quantity having been granted approval in June 2015.
"The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products,” Richard Francis, the CEO of Sandoz, said in a statement. “We look forward to bringing this product to patients and healthcare professionals and providing a full range of patient support services for Glatopa through GlatopaCare.”
A thrice-weekly therapy, injectable glatiramer acetate is an AP-rated, fully substitutable generic variety of Teva Pharmaceuticals’ own glatiramer acetate injection, Copaxone. It was developed through a collaborative agreement between Sandoz and Momenta Pharmaceuticals.
With its approval, the Sandoz product joins Mylan’s duo of generics, which were approved in October 2017. The Teva product they are modeled after was the most prescribed treatment for relapsing forms of MS in the past few years, with sales eclipsing $4 billion. Almost half a million US patients have MS, with 85% suffering relapses.
According to Sandoz, it will offer a $0 co-pay support program, called Sandoz GlatopaCare, for patients that qualify. It also says that to aid in patient confidence with injection administration, the program will offer personalized injection training, in addition to 24-hour access to nurses for glatiramer acetate-related questions and a free “starter kit,” including an injection device that was designed to with prefilled syringes for both dosing options.
Compared with placebo, the most common adverse effects (AEs) with glatiramer acetate injection 20mg/mL patients were such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common AE with glatiramer acetate injection 40mg/mL vs placebo was erythema (22% vs 2%).
Compared with placebo, approximately 12% more of glatiramer acetate injection 20mg/mL patients and approximately 2% more of glatiramer acetate injection 40mg/mL patients experienced a least 2 symptoms that occurred within minutes of the injection. Those included flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms “generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms,” according to Sandoz
Transient chest pain was noted in 7% more glatiramer acetate injection 20mg/mL patients than those on placebo, and approximately 1% more of glatiramer acetate injection 40mg/mL patients. The relationship of this chest pain to an injection was not always understood.
Related Coverage >>>
The Clinical Focus condition center at NeurologyLive, MD Magazine's new sister site, provides even more extensive coverage from the multiple sclerosis space, as well as updates from the field’s most prominent conferences.